|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||145.202 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.
A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:
Emylcamate also has a faster intra-parenteral onset then meprobabamate, 3 minutes compared with 35. 
- Shorter E (August 2004). "Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia" [Looking back: a new possible path for drug discovery in psychopharmacology.] (PDF). Revista de Psiquiatria do Rio Grande do Sul. (in Portuguese). 26 (2): 196–203.